Phage therapy atlas
All 33 phage therapies in the registry, joined to the bacteria they target, their phage family or class, the infections their trials enrol, routes and shared sponsors. Those that share things sit near each other, so the field's clusters show up on their own. Click a dot to see what it connects to; drag to rearrange or pan; zoom with the + and − buttons, Ctrl-scroll or a pinch.
No confirmed trial (7)Early phase 1 / phase 1 (7)Phase 2 (16)Phase 3 (3)Approved (0)
Stage is the furthest a product has got: an approval anywhere, else the highest phase among its confirmed trials. Infections come from those trials' conditions, grouped; they appear once the weekly trial snapshot has linked a product's trials.
All phage therapies
| Product | Family | Stage | Target bacterium | Route | Trials in |
|---|---|---|---|---|---|
| DP-QB-PSA-005 (DP-QB-PSA-005) | Caudoviricetes | Phase 3 | Pseudomonas aeruginosa | Bone and joint | |
| DP-QB-STA-005 (DP-QB-STA-005) | Caudoviricetes | Phase 3 | Staphylococcus aureus | Bone and joint | |
| MP101 (MP101) | Caudoviricetes | Phase 3 | Pseudomonas aeruginosa | Gut and liver, Lungs and cystic fibrosis | |
| AP-PA02 (AP-PA02) | Caudoviricetes | Phase 2 | Pseudomonas aeruginosa | inhaled | Lungs and cystic fibrosis |
| AP-SA02 (AP-SA02) | Caudoviricetes | Phase 2 | Staphylococcus aureus | intravenous | Bloodstream |
| BACTELIDE (BACTELIDE, PL-03-BM) | Caudoviricetes | Phase 2 | Staphylococcus aureus, Pseudomonas aeruginosa, Klebsiella pneumoniae | topical | Wounds, burns and ulcers |
| BX004 (BX004, BX004-A) | Caudoviricetes | Phase 2 | Pseudomonas aeruginosa | inhaled | Lungs and cystic fibrosis |
| BX005 (BX005, BX005-A) | Caudoviricetes | Phase 2 | Staphylococcus aureus | topical | |
| DUOFAG (DUOFAG) | Caudoviricetes | Phase 2 | Staphylococcus aureus, Pseudomonas aeruginosa | topical | Wounds, burns and ulcers |
| EcoActive (EcoActive) | Caudoviricetes | Phase 2 | Escherichia coli | oral | Gut and liver |
| LBP-EC01 (LBP-EC01) | Caudoviricetes | Phase 2 | Escherichia coli | intraurethral, intravenous | Urinary tract |
| PP1493 (PP1493) | Caudoviricetes | Phase 2 | Staphylococcus aureus | intravenous, inhaled | Bone and joint |
| PP1815 (PP1815) | Caudoviricetes | Phase 2 | Staphylococcus aureus | intravenous, inhaled | Bone and joint |
| ShigActive (ShigActive) | Caudoviricetes | Phase 2 | Shigella | oral | Gut and liver |
| SNIPR001 (SNIPR001) | Caudoviricetes | Phase 2 | Escherichia coli | oral | Bloodstream, Healthy volunteers |
| TP-102 (TP-102) | Caudoviricetes | Phase 2 | Pseudomonas aeruginosa, Staphylococcus aureus, Acinetobacter baumannii | topical | Bone and joint, Wounds, burns and ulcers |
| TP-122A (TP-122, TP-122A) | Caudoviricetes | Phase 2 | Pseudomonas aeruginosa | Lungs and cystic fibrosis | |
| VRELysin (VRELysin) | Caudoviricetes | Phase 2 | Enterococcus | oral | Colonisation |
| WRAIR-PAM-CF1 (WRAIR-PAM-CF1) | Caudoviricetes | Phase 2 | Pseudomonas aeruginosa | Lungs and cystic fibrosis | |
| AB-SA01 (AB-SA01) | Herelleviridae | Phase 1 | Staphylococcus aureus | intravenous | Healthy volunteers |
| AchromoPhage (AchromoPhage) | Caudoviricetes | Phase 1 | Achromobacter | Lungs and cystic fibrosis | |
| DP-QB-MYA-002 (DP-QB-MYA-002) | Caudoviricetes | Phase 1 | Mycobacterium abscessus | ||
| Muddy (Muddy_HRMN0052) | Caudoviricetes | Phase 1 | Mycobacterium abscessus | intravenous | Lungs and cystic fibrosis |
| NTR-101 (NTR-101) | Caudoviricetes | Phase 1 | Enterococcus faecalis | Gut and liver | |
| PGX-0100 (PGX-0100) | Caudoviricetes | Phase 1 | Staphylococcus aureus, Pseudomonas aeruginosa, Klebsiella pneumoniae | topical | Wounds, burns and ulcers |
| WPP-201 (WPP-201) | Caudoviricetes | Phase 1 | Pseudomonas aeruginosa, Staphylococcus aureus, Escherichia coli | topical | Wounds, burns and ulcers |
| AB-PA01 (AB-PA01) | Caudoviricetes | No confirmed trial | Pseudomonas aeruginosa | intravenous, inhaled | |
| BFC-1 (BFC-1) | Caudoviricetes | No confirmed trial | Pseudomonas aeruginosa, Staphylococcus aureus | topical | |
| BX211 (BX211) | Caudoviricetes | No confirmed trial | Staphylococcus aureus | ||
| PP1131 (PP1131) | Caudoviricetes | No confirmed trial | Pseudomonas aeruginosa | topical | |
| Pyophage (Pyophage) | Caudoviricetes | No confirmed trial | Staphylococcus, Streptococcus, Enterococcus, Escherichia coli, Proteus mirabilis, Pseudomonas aeruginosa | intravesical | |
| Stafal (Stafal) | Herelleviridae | No confirmed trial | Staphylococcus aureus | ||
| T4 coliphage cocktail (Nestlé) | Straboviridae | No confirmed trial | Escherichia coli | oral | Gut and liver |